Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
18.04
+0.84 (4.88%)
At close: Jul 16, 2026, 4:00 PM EDT
18.04
0.00 (0.00%)
Pre-market: Jul 17, 2026, 7:13 AM EDT
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Amneal Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $18.25. The average 1-year stock price forecast is 1.16% higher than the current stock price, while the lowest is $16 (-11.31%) and the highest is $23 (+27.49%).
Price Target: $18.25 (+1.16%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 2 | 2 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Buy Maintains $19 → $23 | Buy | Maintains | $19 → $23 | +27.49% | Jul 15, 2026 |
| Barclays | Barclays | Buy Maintains $16 | Buy | Maintains | $16 | -11.31% | Jun 11, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $17 | Buy | Maintains | $17 | -5.76% | Jun 4, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Reiterates $17 | Buy | Reiterates | $17 | -5.76% | May 28, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Apr 23, 2026 |
Financial Forecast
Revenue This Year
3.11B
from 3.02B
Increased by 2.89%
Revenue Next Year
3.33B
from 3.11B
Increased by 7.19%
EPS This Year
0.99
from 0.83
Increased by 18.93%
EPS Next Year
1.12
from 0.99
Increased by 13.79%
EPS and Forward PE are based on non-GAAP adjusted numbers.